Please login to the form below

Not currently logged in

Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial

Results showing that the drug is an improvement on Xalkori were released at ESMO 2020 virtual congress

Pfizer’s Lorbrena has come out on top in a head-to-head trial against its older ALK inhibitor Xalkori in previously untreated non-small cell lung cancer (NSCLC) with this specific genetic mutation.

Lorbrena (lorlatinib) reduced the risk of disease progression or death by 72% in ALK-positive NSCLC patients compared to Xalkori (crizotinib) in the phase 3 CROWN trial, presented over the weekend at the 2020 European Society for Medical Oncology (ESMO) virtual congress.

In the same trial, the progression-free survival rate was not yet estimable for Lorbrena, compared to 9.3 months for Xalkori. The intracranial objective response rate was 82% in patients with measurable brain metastases, with a complete response rate of 71% associated with Lorbrena treatment.

Despite the NSCLC market being largely dominated by Merck & Co/MSD’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in around 3-5% of all cases.

Follow-up ALK inhibitors are particularly crucial in this treatment setting, given that many patients experience tumour progression after initial treatment and often require a second- or third-line option. It is also important to note that central nervous system progression often occurs in this type of cancer, wherein the cancer spreads to the brain.

“These results of the CROWN study support the use of Lorbrena as a highly effective first-line therapy for patients with advanced ALK-positive non–small cell lung cancer,” said lead study author Ben Solomon, a medical oncologist in the Lung Service and the Head and Neck service.

The company added that it also intends to share the results from the study with the US Food and Drug Administration (FDA) and other health regulators across the globe to support its approval ambitions.

Currently, Lorbrena is approved only in the second-line setting, for patients who have already been treated with one or more therapies, including Xalkori and treatments from other competitors.

Article by
Lucy Parsons

21st September 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

The other side of … Crohn’s disease
What patients say is their truth about living with chronic conditions. “I want to believe in my doctor but I feel more comfortable getting my guidance elsewhere.”...
OPEN Health brings the Best of Both Worlds to MAPS EMEA 2020
1000 Voices Survey
The patient voice is key to creating meaningful changes in healthcare; to drive patients to be more actively involved in their care, which leads to better outcomes. So, we went...